Report Sections

See All Reports

  • HP:0007018: Attention deficit hyperactivity disorder
  • Pneumonia (359) Respiratory tract infection (38) Neoplasm (36) Abnormality of the cardiovascular system (34) Diabetes mellitus (33) Depressivity (29) Acute kidney injury (27) Hypoxemia (26) Hypertension (24) Abnormal lung morphology (24) Thromboembolism (22) Anosmia (20) Myocardial infarction (20) Arthritis (19) Type II diabetes mellitus (18) Stroke (16) Pulmonary embolism (16) Mental deterioration (15) Abnormality of coagulation (15) Pulmonary fibrosis (15) Chronic pulmonary obstruction (15) Abnormality of the kidney (14) Autistic behavior (14) Rheumatoid arthritis (14) Leukemia (14) Interstitial pneumonitis (14) Pulmonary obstruction (14) Asthma (13) Chronic pain (13) Congestive heart failure (12) Deep venous thrombosis (12) Neoplasm of the lung (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Ulcerative colitis (11) Crohn's disease (11) Type I diabetes mellitus (10) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Chronic kidney disease (9) Myocarditis (9) Behavioral abnormality (8) Psychosis (8) Dementia (8) Alzheimer disease (8) Carcinoma (8) Low levels of vitamin D (8) Sepsis (8) Infertility (7) Peripheral arterial stenosis (7) Renal insufficiency (6) Lymphopenia (6) Dysphagia (6) Lymphoma (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Breast carcinoma (6) Psoriasiform dermatitis (6) Abnormality of the gastrointestinal tract (6) Fatigue (6) Encephalopathy (5) Premature birth (5) Bronchiectasis (5) Difficulty walking (5) Gastroparesis (5) Immunodeficiency (5) Obstructive sleep apnea (5) Autoimmunity (5) Knee osteoarthritis (5) Sleep apnea (5) Prostate cancer (5) Allergy (5) Non-small cell lung carcinoma (5) Schizophrenia (5) Neoplasm of the large intestine (5) Seizure (4) Hepatic fibrosis (4) Cardiac arrest (4) Weight loss (4) Migraine (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Neoplasm of the pancreas (4) Colon cancer (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Inflammatory abnormality of the skin (4) Neoplasm of head and neck (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Obsessive-compulsive behavior (3) Eczema (3) Atopic dermatitis (3) Spastic diplegia (3) Abnormal heart morphology (3) Cardiomyopathy (3) Fever (3) Hypothermia (3) Headache (3) Celiac disease (3) Reduced factor VIII activity (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Abnormal anterior horn cell morphology (3) Amyotrophic lateral sclerosis (3) Cystoid macular edema (3) Arrhythmia (3) Cutaneous melanoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Spasticity (2) Meningitis (2) Abnormal joint morphology (2) Hepatic steatosis (2) Hepatic failure (2) Tachycardia (2) Angina pectoris (2) Pancreatitis (2) Abnormality of blood and blood-forming tissues (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Apnea (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Myelodysplasia (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Postprandial hyperglycemia (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) Cervix cancer (2) Small cell lung carcinoma (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Periodontitis (1) IgA deposition in the glomerulus (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Cerebral hemorrhage (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Dilatation (1) Osteomyelitis (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Intermittent claudication (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Venous insufficiency (1) Chronic lymphatic leukemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0007018: Attention deficit hyperactivity disorder

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (11)


    Name (Synonyms) Correlation
    drug745 COVID-19 FACILITY Wiki 0.50
    drug4287 Wearable Medical Device (Empatica E4) Wiki 0.50
    drug3157 Pulse Oximeter Wiki 0.50
    Name (Synonyms) Correlation
    drug747 COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA) Wiki 0.50
    drug749 COVID-19 PCR Swab Wiki 0.50
    drug1666 Guanfacine hydrochloride (SPD503) Wiki 0.50
    drug385 Atomoxetine hydrochloride Wiki 0.50
    drug1994 Interview by psychologists Wiki 0.50
    drug436 BAT2020 Wiki 0.50
    drug3973 The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki 0.50
    drug2916 Placebo Wiki 0.02

    Correlated MeSH Terms (24)


    Name (Synonyms) Correlation
    D001289 Attention Deficit Disorder with Hyperactivity NIH 1.00
    D006948 Hyperkinesis NIH 0.71
    D001997 Bronchopulmonary Dysplasia NIH 0.50
    Name (Synonyms) Correlation
    D008595 Menorrhagia NIH 0.50
    D006929 Hyperaldosteronism NIH 0.50
    D054559 Hyperphosphatemia NIH 0.50
    D004314 Down Syndrome NIH 0.50
    D000309 Adrenal Insufficiency NIH 0.50
    D007008 Hypokalemia NIH 0.50
    D014552 Urinary Tract Infections NIH 0.35
    D009080 Mucocutaneous Lymph Node Syndrome NIH 0.29
    D000067877 Autism Spectrum Disorder NIH 0.27
    D006470 Hemorrhage NIH 0.25
    D004194 Disease NIH 0.24
    D002659 Child Development Disorders, Pervasive NIH 0.20
    D001321 Autistic Disorder NIH 0.15
    D020141 Hemostatic Disorders NIH 0.13
    D001778 Blood Coagulation Disorders NIH 0.13
    D006973 Hypertension NIH 0.10
    D013577 Syndrome NIH 0.05
    D003141 Communicable Diseases NIH 0.04
    D007239 Infection NIH 0.02
    D045169 Severe Acute Respiratory Syndrome NIH 0.02
    D018352 Coronavirus Infections NIH 0.02

    Correlated HPO Terms (10)


    Name (Synonyms) Correlation
    HP:0002487 Hyperkinetic movements HPO 0.71
    HP:0002905 Hyperphosphatemia HPO 0.50
    HP:0002900 Hypokalemia HPO 0.50
    Name (Synonyms) Correlation
    HP:0000846 Adrenal insufficiency HPO 0.50
    HP:0000132 Menorrhagia HPO 0.50
    HP:0000859 Hyperaldosteronism HPO 0.50
    HP:0000729 Autistic behavior HPO 0.27
    HP:0000717 Autism HPO 0.15
    HP:0001928 Abnormality of coagulation HPO 0.13
    HP:0000822 Hypertension HPO 0.10

    Clinical Trials

    Navigate: Correlations   HPO

    There are 4 clinical trials


    1 A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder

    This interventional multicenter dose-optimization Phase IV PASS conducted in Europe and the USA evaluates the comparative long-term safety and efficacy of SPD503 in children and adolescents aged 6 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) for whom stimulants are not suitable, not tolerated, or shown to be ineffective. The study will be conducted in two parts: Study Part A (randomized, double-blinded, parallel-group, placebo- and active comparator-controlled, 3-treatment arm safety and efficacy evaluation of SPD503) and Study Part B (open label SPD503 treatment).

    NCT04085172
    Conditions
    1. Attention Deficit Hyperactivity Disorder (ADHD)
    Interventions
    1. Drug: Guanfacine hydrochloride (SPD503)
    2. Drug: Atomoxetine hydrochloride
    3. Other: Placebo
    MeSH:Hyperkinesis Attention Deficit Disorder with Hyperactivity
    HPO:Attention deficit hyperactivity disorder Hyperactivity Hyperkinetic movements

    Primary Outcomes

    Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments. The RTI task of CANTAB involves elements of decision-making and attention as measured by choice accuracy as well as motor responses, by measuring motor and mental response speeds, and assesses movement time, reaction time, response accuracy, and impulsivity. This outcome measure will be assessed at Week 10 in both Part A and Part B of the study.

    Measure: Change from Baseline in the Reaction Time (RTI) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) at Week 10

    Time: Baseline, Week 10

    Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments. The RTI task of CANTAB involves elements of decision-making and attention as measured by choice accuracy as well as motor responses, by measuring motor and mental response speeds, and assesses movement time, reaction time, response accuracy, and impulsivity. This outcome measure will be assessed at Week 18 in Part A of the study.

    Measure: Change from Baseline in the Reaction Time (RTI) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) at Week 18

    Time: Baseline, Week 18

    Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments. The RTI task of CANTAB involves elements of decision-making and attention as measured by choice accuracy as well as motor responses, by measuring motor and mental response speeds, and assesses movement time, reaction time, response accuracy, and impulsivity. This outcome measure will be assessed at Week 49 in both Part A and Part B of the study.

    Measure: Change from Baseline in the Reaction Time (RTI) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) at Week 49

    Time: Baseline, Week 49

    Secondary Outcomes

    Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments. Cognitive domain, sustained attention will be measured by the CANTAB RVP task. RVP measures the ability to sustain attention over time and is a sensitive measure of frontal-parietal function. In this task, single digits appear in a pseudo--random order at a rate of 100 digits per minute in a box at the center of the screen. Participants are to detect a 3-digit target sequence (e.g. 2-4-6) and respond by pressing a button at the bottom of the screen when the final number of the sequence appears on the screen.

    Measure: Change from Baseline in the Rapid Visual Information Processing (RVP) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) in Both Part A and Part B at Specified Time Points

    Time: Part A: Baseline, Week 10, Week 18, Week 49 Part B: Baseline, Week 10, Week 49

    Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments, SWM is a component of cognitive executive function which is measured by SWM task of CANTAB between the errors. The ability to retain spatial information and manipulate remembered items in working memory will be measured with the SWM task of CANTAB which is self-ordered and assesses the individual's ability to strategize heuristically. The test is a sensitive measure of frontal lobe and executive dysfunction.

    Measure: Change from Baseline in the Spatial Working Memory (SWM) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) in Both Part A and Part B at Specified Time Points

    Time: Part A: Baseline, Week 10, Week 18, Week 49 Part B: Baseline, Week 10, Week 49

    Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments.Response control or inhibition cognitive domain will be measured by the CANTAB SST. SST measure response inhibition. The participant must respond to an arrow stimulus by touching either of 2 choices depending on the direction the arrow points. If an audio tone is present, the participant is not to respond.

    Measure: Change from Baseline in the Stop Signal Task (SST) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) in Both Part A and Part B at Specified Time Points

    Time: Part A: Baseline, Week 10, Week 18, Week 49 Part B: Baseline, Week 10, Week 49

    Description: The neurocognitive function effects of SPD503 on adolescents and children diagnosed with ADHD will be evaluated using the CANTAB cognitive assessments. Recognition memory of cognition domain will be measured by the CANTAB DMS task. DMS measures both simultaneous matching and short-term visual memory. The participant is shown a complex visual pattern (the sample) and after a brief delay, 4 similar patterns. The participant must identify the pattern that matches the sample.

    Measure: Change from Baseline in the Delayed Matching to Sample (DMS) Task of the Cambridge Automated Neuropsychological Test Battery (CANTAB) in Both Part A and Part B at Specified Time Points

    Time: Part A: Baseline, Week 10, Week 18, Week 49 Part B: Baseline, Week 10, Week 49

    Description: Sexual maturation will be measured by Tanner stage. The stage of puberty or sexual maturation will be evaluated for each participant according to Tanner staging. The Tanner stage for genitals (male, stages I-V), breasts (females, stages I-V), and pubic hair (both sexes, stages I-V) will be documented at the specified times.

    Measure: Tanner Stage in Both Part A and Part B at Specified Time Points

    Time: Part A: Baseline, Week 10, Week 18, Week 49 Part B: Baseline, Week 10, Week 49

    Description: Physical examinations will include height and weight. Growth will be measured by weight, height, and BMI. Body mass index is a measure of body fat based on height and weight. Vital signs will be assessed based on blood pressure, pulse rate, respiratory rate and body temperature in both Part A and Part B. The HR, PR interval, QRS interval, and QT interval will be measured from all ECGs and the QTcB and QTcF assessed at specified time points in both Part A and Part B of the study.

    Measure: Number of participants with clinically significant changes in Vital signs, ECG, Physical Examination

    Time: From start of study drug administration up to follow up (week 52)

    Description: Psychiatric symptoms will be measured by the Brief Psychiatric Rating Scale for Children (BPRS-C) total score. The 21 items of the clinician-rated BPRS-C are grouped into the following 7 scales: depression, anxiety, psychomotor excitation, behavior problems, withdrawal retardation, thinking disturbance, and organicity. Each item of the 21 items is clinician-graded using the following 7-point severity Likert-scale from 0 to 6 (not present=0; very mild=1; mild=2; moderate=3; moderately severe=4; severe=5; extremely severe=6. BPRS-C will be assessed at specified time points in both Part A and Part B.

    Measure: Brief Psychiatric Rating Scale for Children (BPRS-C)

    Time: Part A: Baseline, Week 10, Week 18, Week 23, Week 36 and Week 49 Part B: Baseline, Week 10, Week 23, Week 36 and Week 49

    Description: The C-SSRS is a structured tool to assess suicidal ideation and behavior. A maximum of 19 items will be completed as follows: 7 items are required, a potential 10 additional items will be completed upon a positive response to a required item, and 2 items completed if suicide or suicide-like behavior is observed during the interview. The C-SSRS uses dichotomous scales (i e, yes or no), Likert scales, and text or narrative to further describe thoughts or behaviors. C-SSRS Score will be assessed at specified time points in both Part A and Part B.

    Measure: Columbia- Suicide Severity Rating Scale (CSSRS)

    Time: Baseline (from start of study drug administration) to Week 52

    Description: UKU rating scale was developed for clinicians to assess side effects of psychopharmacological medications based on interviews and other relevant source information. UKU items relevant to the established safety profile of SPD503 such as Increased Duration of Sleep, Asthenia or Lassitude or lncreased Fatigability, Sleepiness or Sedation, and Orthostatic Dizziness. UKU rating scale will be assessed at specified time points in both Part A and Part B.

    Measure: Udvalg for Kliniske Unders√łgelser (UKU) Side Effect Rating Scale

    Time: Part A: Baseline, Week 10, Week 18, Week 23, Week 36, Week 49, Week 50, Week 51 and Week 52 Part B: Baseline, Week 10, Week 23, Week 36, Week 49, Week 50, Week 51 and Week 52

    Description: Sedative effects will be measured by participant ratings on the Pediatric Daytime Sleepiness Scale (PDSS). The PDSS is a self-reported assessment of daytime sleepiness in children aged 11 to 15 years. PDSS questionnaire was designed to be easy to administer, score, and interpret. Sleepiness-related questions are based on previous research of situations that can be sensitive to sleep loss in this age group. The 8 questions are scored on Likert-scale from 0 to 4 (never=0; seldom=1; sometimes=2; frequently=3; always=4). The total score on the PDSS can range from 0 (never sleepy) to 32 (always sleepy). PDSS will be assessed at specified time points in both Part A and Part B.

    Measure: Pediatric Daytime Sleepiness Scale (PDSS)

    Time: Part A: Baseline, Week 10, Week 18, Week 23, Week 36 and Week 49 Part B: Baseline, Week 10, Week 23, Week 36 and Week 49

    Description: The ADHD-RS-5 (DuPaul et al., 2016) is used widely by mental health, educational, and medical practitioners in screening, diagnosis, and treatment evaluation to determine the frequency and severity of ADHD symptoms and impairments in children and adolescents. Attention-deficit/hyperactivity disorder symptoms is measured by the investigator-administered ADHD Rating Scale-5 (ADHD-RS-5) total score and hyperactivity/impulsivity and inattentiveness symptoms as subscale scores. The ADHD-RS-5 is based on the diagnostic criteria for ADHD as described in the DSM-5 and consists of 2 symptom subscales, inattention and hyperactivity-impulsivity, each with 9 items and a total scale of 18 items. Each item in the subscale is scored with a value ranging from 0 (no symptoms) to 3 (severe symptoms). The total score can range from 0 to 54. ADHD-RS-5 Total Score and Subscales wiil be assessed at specified time points in both Part A and Part B.

    Measure: ADHD Rating Scale-5 (ADHD-RS-5) Total Score and Subscales

    Time: Part A: Baseline, Week 1, Week 10, Week 18, Week 23, Week 36 and Week 49 Part B: Baseline, Week 10, Week 23, Week 36 and Week 49

    Description: Global clinical measurement of ADHD improvement as measured by Clinical Global Impression-Improvement (CGI-I) using the Clinical Global Impression-Severity (CGI-S) to establish baseline. The CGI scale will be used to evaluate the severity of mental illness over time. The CGI-S will be administered to assess the severity of mental illness at baseline. The CGI-S is scored on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). The CGI-I is also scored on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). CGI-I will be measured at specified time points in both Part A and Part B.

    Measure: Clinical Global Impression-Improvement (CGI-I)

    Time: Part A: Week 1, Week 10, Week 18, Week 23, Week 36 and Week 49 Part B: Week 10, Week 23, Week 36 and Week 49

    Description: The Parent Report Form of the Child Health and Illness Profile - Child Edition (CHIP-CE:PRF) will be administered to provide information on self-esteem and school functioning in pediatric participants diagnosed with ADHD. The 5 domains and 12 subdomains covered in the 76 items comprising the CHIP-CE:PRF. Satisfaction: with health (7 items) and self (4 items); Comfort: physical (9 items) and emotional symptoms (9 items) and activity restrictions (4 items) due to illness; Resilience: behaviors and family involvement (8 items) in activities likely to enhance health, Social problem-solving (5 items),Physical activity (6 items); Risk avoidance: behaviors that if not avoided are likely to pose risks to health: Individual risk avoidance (4 items), Threats to achievement (10 items); Achievement: developmentally appropriate role functioning in school and with peers: Academic performance (5 items), Peer relations (5 items). CHIP-CE: PRF will be assessed in both Part A and Part B.

    Measure: Child Health and Illness Profile - Child Edition: Parent Report Form (CHIP-CE:PRF)

    Time: Part A: Baseline, Week 10, Week 18, Week 23, Week 36 and Week 49 Part B: Baseline, Week 10, Week 23, Week 36 and Week 49

    Description: School performance will be measured by teacher ratings of academic skills using the APRS at specified time points in both Part A and Part B. The APRS is a reliable rating scale that has been shown to be valid in assessing teacher perceptions of the quality of a student's academic competency. The scale includes 19 items that are directed toward work performance in various participant areas; academic success, behavioral control in academic situations, and attention to assignments. Teachers mark responses in a Likert-scale format from 1 (never or poor) to 5 (very often or excellent). From the APRS, a total score and the following 3 subscale scores are calculated: academic success, impulse control, and academic productivity.

    Measure: Academic Performance Rating Scale (APRS)

    Time: Part A: Baseline, Week 10, Week 18, Week 23, Week 36 and Week 49 Part B: Baseline, Week 10, Week 23, Week 36 and Week 49
    2 Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs

    The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.

    NCT04278404
    Conditions
    1. Coronavirus Infection (COVID-19)
    2. Pulmonary Arterial Hypertension
    3. Urinary Tract Infections in Children
    4. Hypertension
    5. Pain
    6. Hyperphosphatemia
    7. Primary Hyperaldosteronism
    8. Edema
    9. Hypokalemia
    10. Heart Failure
    11. Hemophilia
    12. Menorrhagia
    13. Insomnia
    14. Pneumonia
    15. Skin Infection
    16. Arrythmia
    17. Asthma in Children
    18. Bronchopulmonary Dysplasia
    19. Adrenal Insufficiency
    20. Fibrinolysis; Hemorrhage
    21. Attention Deficit Hyperactivity Disorder
    22. Multisystem Inflammatory Syndrome in Children (MIS-C)
    23. Kawasaki Disease
    24. Coagulation Disorder
    25. Down Syndrome
    Interventions
    1. Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    MeSH:Infection Communicable Diseases Urinary Tract Infections Coronavirus Infections Severe Acute Respiratory Syndrome Bronchopulmonary Dysplasia Down Syndrome Menorrhagia Hypertension Hemostatic Disorders Mucocutaneous Lymph Node Syndrome Blood Coagulation Disorders Hyperphosphatemia Hypokalemia Adrenal Insufficiency Hyperaldosteronism Disease Syndrome Hemorrhage Attention Deficit Disorder with Hyperactivity
    HPO:Abnormality of coagulation Abnormality of the coagulation cascade Adrenal insufficiency Attention deficit hyperactivity disorder Hyperaldosteronism Hyperphosphatemia Hypertension Hypokalemia Menorrhagia Primary hyperaldosteronism

    Primary Outcomes

    Measure: Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Elimination rate constant (ke) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Half-life (t1/2) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Absorption rate constant (ka) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: AUC (area under the curve) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Maximum concentration (Cmax) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Time to achieve maximum concentration (Tmax) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
    3 Clinical Evolution and Parenting in Children and Adolescents With Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder Quarantined Because of Covid-19 Outbreak

    In response to the coronavirus disease 2019 (covid-19) outbreak, the home confinement of the population ordered by governments in many countries raise questions about its impact on individuals' physical and mental health in the short and longer term. In children, reduced physical activity, changes in lifestyle, disturbances in sleep patterns, lack of in-person contact with peers, poor or inadequate understanding of health risks may be risk factors of anxiety, stress, fatigue, sleep disorders (Brooks et al, 2020; Wang et al, 2020; Sprang et al, 2013). These problematic effects could be modulated by social factors (housing in urban or rural areas, availability of personal space at home, parenting stress, etc.) (Cluver et al, 2020; Liu et al, 2020).

    NCT04416360
    Conditions
    1. Autism Spectrum Disorder
    2. Attention-deficit Hyperactivity Disorder
    Interventions
    1. Other: Interview by psychologists
    MeSH:Hyperkinesis Disease Autistic Disorder Attention Deficit Disorder with Hyperactivity Autism Spectrum Disorder Child Development Disorders, Pervasive
    HPO:Attention deficit hyperactivity disorder Autism Autistic behavior Hyperactivity Hyperkinetic movements

    Primary Outcomes

    Description: composition, home confinement, change in the environment, personal room at home, screens with internet access, parents' current professional status, teleworking, care, family concerns related to Covid-19, parenting stress, schooling, recurrent complaints.

    Measure: Interview of the parents : contextual data

    Time: Baseline

    Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)

    Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general

    Time: Baseline

    Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)

    Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general

    Time: 1 month

    Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)

    Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general

    Time: 3 months

    Description: Data relating to disease and management of care. Experience of the referring caregiver.

    Measure: Interview of the referring caregiver : data relating to disease and management of care

    Time: 3 months
    4 Brain Imaging and Infant Development

    The aims of the BIBS Study The Brain Imaging in Babies study (BIBS) aims to improve understanding of how a baby's brain develops from before birth, up until 3-4 years of age. Working with children from a variety of backgrounds and communities, the investigators use a combination of state-of-the-art diagnostic tools such as MRI scans alongside traditional behavioural assessments to capture the earliest information on infant brain development. The focus of the BIBS study MRI scanning is a safe way of producing detailed images using strong magnetic fields and radio waves. It does not use X-ray. Along with learning more about brain development in general, the investigators also try to identify features that may in future help predict whether a child will or will not develop traits of conditions such as Autism Spectrum Disorder (ASD) or Attention Deficit Hyperactivity Disorder (ADHD). Long-term, this may help target useful interventions early on, helping children who are most in need. Since COVID-19 arrived in the United Kingdom (U.K.) in 2020, the investigators have been given ethical approval to include testing for this infection in the mothers and children participating in the study. This may provide an opportunity to better understand how mother and baby respond to infections. The investigators particularly welcome mothers who have had a positive COVID-19 test during their pregnancy to join the study.

    NCT04443179
    Conditions
    1. Autism Spectrum Disorder
    2. Attention Deficit Hyperactivity Disorder
    3. Neurodevelopmental Conditions
    4. COVID-19
    MeSH:Disease Attention Deficit Disorder with Hyperactivity Autism Spectrum Disorder
    HPO:Attention deficit hyperactivity disorder Autistic behavior

    Primary Outcomes

    Measure: Neurodevelopmental Outcomes

    Time: 3-4 years of age

    HPO Nodes


    HP:0007018: Attention deficit hyperactivity disorder
    Genes 377
    PRNP ZIC2 MLH1 LIG4 NTNG1 KCNA2 TRIO SETBP1 DYNC1I2 GNAQ MID2 NODAL DYRK1A HDC SH2B1 ZNF41 CDH2 RAB39B LIMK1 CIC CNKSR2 SCN8A LHCGR USP27X EEF1A2 NR2F1 CSGALNACT1 SIX3 ACTL6B PAK3 SLITRK1 GP1BB GATA4 MLXIPL IQSEC1 ADNP C12ORF4 CDK19 TKT SEC24C DHTKD1 SETD2 SYNJ1 RREB1 BMPR1A ARVCF YWHAG DMD PMS1 RLIM IQSEC2 CLIP2 SIM1 TBX1 WWOX PIEZO2 SETD5 SYNGAP1 PPP3CA DLL1 DISP1 FTSJ1 HCFC1 GAS1 ARF1 FOXH1 ODC1 ELN IKBKG SPG7 BAZ1B OCRL ACTL6A TBC1D24 METTL5 NF1 TCF20 JMJD1C STAG2 UPF3B UFD1 MED13 ZMIZ1 FBXW11 CHRNA7 RFC2 SIX3 TSC1 DLL1 AP3B2 SIX3 TDGF1 THRB GTF2I CACNA1A MLH3 NECAP1 GNB5 PRKCG NSD1 GABRB2 OPHN1 SATB2 USP7 FAN1 FGF12 STS CXORF56 SEMA3E MSH2 FOXH1 SETD5 GABRA2 ACTL6B SLC2A1 ZNF711 CDON CDON TBX1 HERC2 MED12 DLG3 NLGN1 TRAK1 GRIA4 USP9X TLK2 GAS1 RPS6KA3 SCN3A CDK8 KIF11 TIMM8A PARS2 PPM1D DRD4 PWAR1 JRK MED12 MED12L MYT1L RAI1 TKT ZIC2 MYT1L ARID2 EPCAM CRBN CACNA1H CYFIP2 NODAL NBN SMPD1 GABRG2 CACNA1B FOXH1 CLCN4 KMT2A SHH DISP1 RAD21 ABCD1 UBA5 STS DDX6 MCTP2 CSNK2A1 PANK2 TRIO PPP1R12A FGF8 MAGEL2 GLI2 PTCHD1 DYM NPAP1 PHIP TANC2 DISP1 TGIF1 WAC PSMD12 FGD1 SLC13A5 SLC6A8 SNORD116-1 SRPX2 FGF8 ARHGEF6 UBE3A MAP1B GABRA5 TDGF1 HDAC4 TGFBR2 PTCH1 BCR SH3KBP1 GDI1 WDFY3 TDGF1 TSC2 GLI2 FGF8 YY1 SHH CARS1 TUBB2B IFNG GLI2 FGFR1 SYP RPS20 DHDDS GAS1 BCORL1 BPTF RERE NIPBL MKRN3 GNE COMT SNORD115-1 TBX1 TGIF1 SPRED1 GLUD1 NDP WAC GTF2IRD1 SCN8A TSC1 TSPAN7 FMR1 CDON WAC GRIN2D NUS1 KCNA2 STAG2 DEAF1 PAH DNM1 FLI1 GABRG2 PTCH1 FGD1 SIX3 DALRD3 RAI1 GNE TMCO1 YWHAG SMC3 FOXH1 PIK3CA ZDHHC9 NKAP TAF1 RAI1 FLII CNKSR2 HOXA2 TGIF1 RERE SEMA4A ZIC2 MED13 HDAC8 KMT2E AGTR2 IPW RIC1 APC2 AUTS2 PAH ASPM GABRG2 SZT2 KRAS ALG13 DRD5 DOCK3 FGF8 SHH ARV1 TDGF1 STXBP1 UPF3B GALC DLL1 STAG2 BCORL1 PCGF2 TET3 SHH NODAL SLC1A2 TRMT1 NOP56 TGIF1 MED12 PTCH1 ZIC2 SMC1A CLTC HSPG2 MSH6 PWRN1 IGF1 CPLX1 FOXP1 GRIN2A FGFR1 GAS1 TBX1 SIN3A IL1RAPL1 NTRK2 PCNT KCNB1 ELN ALKBH8 TSC2 SLC9A7 POLA1 NDN MECP2 MAPK1 CDON PTCHD1 SOX5 ATP6V1A KDM3B NODAL HCN1 KIF14 TRAPPC4 GRIN2A KAT8 TBL2 DLL1 PTCH1 MED12 DNAJC12 HIRA GLI2 MKRN3-AS1 IQSEC2 SVBP ZNF81 NSUN2 AARS1 GABRB3 RSRC1 PMS2 DLL1 FRMPD4 GABRA1 CHD7 FGFR3 CNKSR2 CRKL ARX TANC2 DHCR7 ZMIZ1 TRAPPC14 TBL1X ACSL4 CLTC SNRPN PHF21A DISP1 DPH1 SH2B1 SMC1A
    Protein Mutations 2
    D203E G143E

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0007018: Attention deficit hyperactivity disorder
    Genes 377
    PRNP ZIC2 MLH1 LIG4 NTNG1 KCNA2 TRIO SETBP1 DYNC1I2 GNAQ MID2 NODAL DYRK1A HDC SH2B1 ZNF41 CDH2 RAB39B LIMK1 CIC CNKSR2 SCN8A LHCGR USP27X EEF1A2 NR2F1 CSGALNACT1 SIX3 ACTL6B PAK3 SLITRK1 GP1BB GATA4 MLXIPL IQSEC1 ADNP C12ORF4 CDK19 TKT SEC24C DHTKD1 SETD2 SYNJ1 RREB1 BMPR1A ARVCF YWHAG DMD PMS1 RLIM IQSEC2 CLIP2 SIM1 TBX1 WWOX PIEZO2 SETD5 SYNGAP1 PPP3CA DLL1 DISP1 FTSJ1 HCFC1 GAS1 ARF1 FOXH1 ODC1 ELN IKBKG SPG7 BAZ1B OCRL ACTL6A TBC1D24 METTL5 NF1 TCF20 JMJD1C STAG2 UPF3B UFD1 MED13 ZMIZ1 FBXW11 CHRNA7 RFC2 SIX3 TSC1 DLL1 AP3B2 SIX3 TDGF1 THRB GTF2I CACNA1A MLH3 NECAP1 GNB5 PRKCG NSD1 GABRB2 OPHN1 SATB2 USP7 FAN1 FGF12 STS CXORF56 SEMA3E MSH2 FOXH1 SETD5 GABRA2 ACTL6B SLC2A1 ZNF711 CDON CDON TBX1 HERC2 MED12 DLG3 NLGN1 TRAK1 GRIA4 USP9X TLK2 GAS1 RPS6KA3 SCN3A CDK8 KIF11 TIMM8A PARS2 PPM1D DRD4 PWAR1 JRK MED12 MED12L MYT1L RAI1 TKT ZIC2 MYT1L ARID2 EPCAM CRBN CACNA1H CYFIP2 NODAL NBN SMPD1 GABRG2 CACNA1B FOXH1 CLCN4 KMT2A SHH DISP1 RAD21 ABCD1 UBA5 STS DDX6 MCTP2 CSNK2A1 PANK2 TRIO PPP1R12A FGF8 MAGEL2 GLI2 PTCHD1 DYM NPAP1 PHIP TANC2 DISP1 TGIF1 WAC PSMD12 FGD1 SLC13A5 SLC6A8 SNORD116-1 SRPX2 FGF8 ARHGEF6 UBE3A MAP1B GABRA5 TDGF1 HDAC4 TGFBR2 PTCH1 BCR SH3KBP1 GDI1 WDFY3 TDGF1 TSC2 GLI2 FGF8 YY1 SHH CARS1 TUBB2B IFNG GLI2 FGFR1 SYP RPS20 DHDDS GAS1 BCORL1 BPTF RERE NIPBL MKRN3 GNE COMT SNORD115-1 TBX1 TGIF1 SPRED1 GLUD1 NDP WAC GTF2IRD1 SCN8A TSC1 TSPAN7 FMR1 CDON WAC GRIN2D NUS1 KCNA2 STAG2 DEAF1 PAH DNM1 FLI1 GABRG2 PTCH1 FGD1 SIX3 DALRD3 RAI1 GNE TMCO1 YWHAG SMC3 FOXH1 PIK3CA ZDHHC9 NKAP TAF1 RAI1 FLII CNKSR2 HOXA2 TGIF1 RERE SEMA4A ZIC2 MED13 HDAC8 KMT2E AGTR2 IPW RIC1 APC2 AUTS2 PAH ASPM GABRG2 SZT2 KRAS ALG13 DRD5 DOCK3 FGF8 SHH ARV1 TDGF1 STXBP1 UPF3B GALC DLL1 STAG2 BCORL1 PCGF2 TET3 SHH NODAL SLC1A2 TRMT1 NOP56 TGIF1 MED12 PTCH1 ZIC2 SMC1A CLTC HSPG2 MSH6 PWRN1 IGF1 CPLX1 FOXP1 GRIN2A FGFR1 GAS1 TBX1 SIN3A IL1RAPL1 NTRK2 PCNT KCNB1 ELN ALKBH8 TSC2 SLC9A7 POLA1 NDN MECP2 MAPK1 CDON PTCHD1 SOX5 ATP6V1A KDM3B NODAL HCN1 KIF14 TRAPPC4 GRIN2A KAT8 TBL2 DLL1 PTCH1 MED12 DNAJC12 HIRA GLI2 MKRN3-AS1 IQSEC2 SVBP ZNF81 NSUN2 AARS1 GABRB3 RSRC1 PMS2 DLL1 FRMPD4 GABRA1 CHD7 FGFR3 CNKSR2 CRKL ARX TANC2 DHCR7 ZMIZ1 TRAPPC14 TBL1X ACSL4 CLTC SNRPN PHF21A DISP1 DPH1 SH2B1 SMC1A
    Protein Mutations 2
    D203E G143E

    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook